Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Metsera (NASDAQ:MTSR) shareholders is whether they should be ...

Metsera holds the No. 232 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG Therapeutics TGTX and ACADIA Pharmaceuticals ACAD are among the top 5 highly rated ...

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Metsera, Inc., a biopharmaceutical company focused on obesity and metabolic diseases, will present four talks at the American Diabetes Association's 85th Scientific Sessions, showcasing its ...

Metsera said the treatment has a half life of about 16 days. The current GLP-1 drugs on the market, such as Wegovy and Zepbound, are dosed weekly, so a monthly option could be more convenient and ...

Metsera has $187.6 million of cash and cash equivalents, according to the filings. Its offering was led by Bank of America Corp., Goldman Sachs Group Inc., Evercore Inc., Guggenheim Securities ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...

Metsera will present clinical data from MET-097i’s Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a ...